87 results about "Pharmacological therapy" patented technology

The invention discloses a lactobacillus rhamnosus strain with antiallergic activity and a preparation method thereof, the strain is lactobacillus rhamnosus Lrn-PG-06, the classification name of the strain is Lactobacillus rhamnosus, the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.3077, the preservation time is March 21, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.3077, and the preservation number is CGMCC No.3077. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus rhamnosus Lrn-PG-06 strain is high in acid resistance, alkali resistance and cholate resistance, high in simulated gastrointestinal fluid resistance and high in oxidation resistance, has the advantage of resisting allergy, and solves the problems that at present, allergic diseases are mainly treated by drugs or are prevented from being in contact with allergens in the environment and food, but due to the fact that the drugs are large in toxic and side effects, the allergens cannot be in contact with the allergens in the environment and food. And allergens causing anaphylaxis are difficult to determine, so that allergic diseases are difficult to treat or prevent.

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

The present application relates to the field of medicinal chemistry and pharmacotherapy, and in particular to a class of bazedoxifene and its preparation method and application. The bazedoxifene derivative is used for gp130 small molecule inhibitor, the compound is a compound shown in formula (I), or a pharmaceutically acceptable salt or ester thereof, and relates to the application of tumor-related activity and the like, in particular the application in preparing drugs for preventing and / or treating diseases related to tumors, especially colorectal cancer.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

Proposed are antibodies specifically binding to PTK7 and a use thereof and, more particularly, PTK7 neutralizing antibodies specifically binding to PTK7 to inhibit PTK function, and a use thereof for inhibiting angiogenesis, cell growth, cell migration, and cell invasion. The human PTK7 neutralizing monoclonal antibodies have been found to independently exhibit an effective inhibitory effect on cancer cell growth, migration, invasion in esophageal squamous cell carcinoma and triple-negative breast cancer, and angiogenesis. Therefore, the human PTK7 neutralizing monoclonal antibodies can be applied to various PTK7-positive carcinomas and angiogenic diseases, and can be further developed as a targeted drug therapy for intractable cancers and angiogenic diseases to be used as a core global treatment drug for the same.

The invention discloses an agonist of a retinoic acid receptor beta and application of the agonist in preparation of a non-small cell lung cancer medicine in the technical field of biological medicine. The agonist of the retinoic acid receptor beta is saturated odd fatty acid heptadecanoic acid C17: 0; according to the research, the expression of a retinoic acid receptor beta can be up-regulated by adding heptadecanoic acid into the NSCLC cells, so that the sensitivity of the NSCLC cells to retinoic acid treatment is improved. When heptadecanoic acid and retinoic acid are combined for use, the activity and migration ability of NSCLC cells can be further inhibited, and apoptosis of the cells is promoted. The result shows that the heptadecanoic acid plays an important role in controlling the sensitivity of the NSCLC cells to the retinoic acid, the combined use of the heptadecanoic acid and the retinoic acid provides a new drug treatment means for treating the NSCLC, and the heptadecanoic acid and the retinoic acid have potential application value in preparing the drug for treating the non-small cell lung cancer.

The present application relates to a kind of pterostilbene piperidine amide derivatives, its preparation method and medical use, belong to the field of medicinal chemistry and pharmacotherapy.The present application uses pterostilbene as raw material, designs, synthesizes a series of pterostilbene piperidine amide compounds with new structure, and its structure is characterized.The method used in the present application to prepare these compounds has the characteristics of easy-to-get raw material, simple operation and high yield, and can quickly synthesize target compounds.Compared with pterostilbene, the pterostilbene piperidine amide derivatives provided in the present application have significant cell proliferation inhibitory effect on tumor cells.

The invention discloses an antibody specifically binding to CD48-1 protein or an antigen binding fragment thereof and application thereof, and belongs to the technical field of biological medicine. The invention further discloses application of the antigen binding fragment specifically binding to the CD48-1 protein, the antibody, polynucleotide, an expression vector, a host cell and the conjugate. The invention also discloses a pharmaceutical composition which comprises one of the antigen binding fragment specifically binding to the CD48-1 protein, an antibody, polynucleotide, an expression vector, a host cell and a conjugate. The antibody or the antigen binding fragment thereof has the beneficial effects that immunological rejection caused by species difference does not exist, and the antibody or the antigen binding fragment thereof has specific binding performance to human CD48-1 full-length protein, can be used for detecting the CD48-1 protein and diagnosing diseases related to the CD48-1 protein, can be used for preparing drugs specifically binding to the CD48-1 protein, and can be used for preparing the CD48-1 protein. The CD48-1 protein related diseases can be treated or prevented, and the CD48-1 protein has a wide application prospect.

The invention provides a method for regulating and controlling proliferation and movement of human peripheral blood T cells by Amuc1100 protein. The method relates to the technologies of separation, activation and culture of human peripheral blood T cells, CCK-8 cell proliferation detection, Transwell cell chemotactic detection, flow cytometry receptor expression body detection and the like. The application of the Amuc1100 protein to treat T cells proves that the protein can significantly down-regulate the expression of CD25 and CXCR4 of the T cells and inhibit T cell proliferation and CXCL12 induced T cell chemotactic movement respectively. The method and research means for in-vitro regulation of T cell proliferation and chemotactic movement can be applied to targeted regulation of T cells and directional migration of intestinal tracts of the T cells, and are used for maintaining the steady state of the intestinal tracts, relieving intestinal inflammations and screening drugs to treat diseases related to the intestinal inflammations.

The present invention provides an effective pharmacological therapy for pathological repetitive behaviours.

The present application belongs to the field of medicinal chemistry and pharmacotherapy, and particularly relates to a chalcone mannich base compound, a pharmaceutical composition and a preparation method and application thereof. The present application takes paeonol as a raw material, and obtains corresponding 3-substituted and 5-amino-methyl-substituted paeonol mannich base through mannich reaction of paeonol, polyoxymethylene and different organic amines. After the 3-substituted and 5-substituted paeonol mannich base is separated through column chromatography, the chalcone mannich base compound is obtained through Claisen-Schmidt reaction of the 3-substituted and 5-substituted paeonol mannich base and benzaldehyde containing different substituents. Experiments prove that the chalcone mannich base compound improves the physical and chemical properties of the chalcone mannich base and improves the drug efficacy, can solve the problem of poor water solubility, and has good anti-tumor cell proliferation activity.

The invention discloses an active polypeptide for promoting healing of oral ulcer and application thereof, and belongs to the technical field of biological medicines. The amino acid sequence of the active polypeptide NPTX3 capable of promoting healing of the oral ulcer is DLKPIAEDIPSLEK. An in-vitro experiment result shows that the polypeptide NPTX3 can remarkably promote the scratch closure of the human immortalized keratinocytes at the concentration as low as 500 pM. Transwell migration experiments further prove that the polypeptide NPTX3 can obviously enhance the migration ability of HaCaT cells at the concentrations of 1nM and 10nM, which prompts that the polypeptide NPTX3 may accelerate wound repair by promoting epithelial cell migration. In an SD (Sprague Dawley) rat oral ulcer model, the ulcer healing rate can be obviously improved by locally applying the polypeptide NPTX3 (1 nM, 10 nM). The polypeptide NPTX3 provided by the invention shows excellent activity of promoting cell migration and tissue repair at an extremely low dose, has the advantages of low effective dose, strong biological activity, high safety and the like, and provides an efficient and mild new choice for drug treatment of oral ulcer.

Compositions and methods relating to a pharmacological therapy for a human genetic disease, specifically mitochondrial DNA depletion-deletions syndromes, and more specifically, those related to mutations in the GUK1 gene. The pharmacological therapy involves the administration of deoxyguanosine (dG), a purine nucleoside phosphorylase (PNP) inhibitor, including but not limited to forodesine, or both.

The application discloses a lenvatinib-polyethylene glycol coupling compound and a preparation method and application thereof. The lenvatinib-polyethylene glycol coupling compound has a structure as shown in the formula (I): in the formula (I), n is greater than or equal to 2. The application further provides a nano preparation containing vinpocetine and the lenvatinib-polyethylene glycol coupling compound and used for manufacturing drugs, which can be applied to tumor treatment, effectively improves the limitation of a single drug treatment method on tumor inhibition, and shows a positive application potential in the tumor treatment field.

Provided is a pharmaceutically acceptable formulation comprising a taxane and an acid-activated 2-hydroxypropyl-β-cyclodextrin (CD). Also provided is a method of treating a patient with a taxane. The method comprises infusing the above formulation into the patient. Additionally provided is a method of preparing the above formulation. Further provided is an infusion bag comprising the above formulation.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The invention belongs to the technical field of biological medicines, and relates to application of an HIF-1alpha inhibitor in preparation of a product for inducing transformation of astrocytes from a pro-inflammatory type to an anti-inflammatory type. The invention reveals that activation of an HIF-1 signal channel is an important mechanism for driving neuroinflammatory response and pro-inflammatory A1 type astrocyte formation, and inhibition of HIF-1 activation can effectively promote generation of neuroprotective A2 type astrocytes. By applying the HIF-1alpha small-molecule inhibitor KC7F2 to astrocytes, HIF-1alpha activation is blocked, and the astrocytes are promoted to be converted from a proinflammatory A1 phenotype to an anti-inflammatory A2 phenotype, so that inflammatory response is inhibited, neurotoxicity is reduced, and a neuron microenvironment is improved. The invention provides a novel intervention strategy based on HIF-1alpha signal regulation and control, and a novel theoretical basis and a novel potential drug treatment scheme are provided for treatment of nervous system injury and related neurodegenerative diseases.

To provide a method for extending progression-free survival (PFS) in a patient with extensive-stage small cell lung cancer (ES-SCLC).SOLUTION: This method comprises treating a patient with extensive-stage small cell lung cancer with a) a human anti-PD-L1 antibody and b) etoposide and a platinum-based therapeutic agent (EP).SELECTED DRAWING: None

The application belongs to the field of gene drugs, and particularly relates to CTRTS, an analog thereof and application thereof. The CTRTS has a nucleotide sequence as shown in SEQ ID NO. 1. The CTRTS analog is CTRTS Agomir, and has a nucleotide sequence as shown in SEQ ID NO. 2. The present application finds that the expression level of CTRTS is reduced when doxorubicin induces cardiotoxicity; overexpression of CTRTS can significantly inhibit doxorubicin-induced cardiotoxicity, and plays an important role in the regulation of myocardial cell death. The existing drug has limited therapeutic effect, therefore, CTRTS plays an important role in the regulation of myocardial cell death, can regulate the doxorubicin-induced cardiotoxicity treatment by participating in the regulation of the myocardial cell death process, so as to improve the clinical prognosis effect.

The invention discloses application of circKIAA1617 serving as an ER < + > breast cancer treatment target and a prognostic marker. According to the invention, circKIAA1617 is found to be used as an ER + breast cancer diagnosis biomarker and a drug treatment target for the first time; experiments prove that in-vitro and in-vivo proliferation of ER + breast cancer cells can be inhibited by interfering expression of circKIAA1617, and proliferation and stemness progress of ER + breast cancer can be promoted by circKIAA1617; the circKIAA1617 can be used for promoting lipophagy of ER < + > breast cancer cells; therefore, the circKIAA1617 plays a role in promoting the cancer in the development of the ER + breast cancer.

The present invention relates to novel compounds of general Formula I with multifaceted pharmacological activities. The compounds of the invention exhibit SGLT1, SGLT2, and DPP4 inhibition. The present invention also provides processes and intermediates to obtain the compounds of the invention, pharmaceutical compositions comprising encompasses the compounds, processes and intermediates for the synthesis of the compounds, pharmaceutical compositions, combinations, medicaments, therapeutical uses and methods for the treatment of diseases, for instance, cardiovascular and renal diseases, including heart failure, chronic kidney disease, diabetes mellitus, diabetic nephropathy and myocardial infarction. [Chem. 1] Compound of Formula I (I)

Described herein are methods of treating cancer using a small molecule TEAD inhibitor and an additional agent. Described herein are methods of treating fibrosis disease using a small molecule TEAD inhibitor.

Provided is a medicament for treating or preventing cerebral hemorrhage, which contains, as an active ingredient, a compound of the following formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof.

The invention belongs to the technical field of intelligent drug delivery control, and particularly discloses a colon tumor drug delivery method and system based on AI control, and the method comprises the steps: collecting and preprocessing whole genome sequencing, radiomics, clinical pathology and historical drug treatment response data of a patient, extracting tumor image features, and carrying out drug delivery. The method comprises the following steps: screening oxaliplatin response related gene mutation markers by combining Lasso regression with a Cox model, forming feature vectors by t-SNE dimensionality reduction clinical pathological data, training a model through a gradient boosting tree and deep neural network fusion algorithm, taking oxaliplatin response probability as output, and recommending an FOLFOX scheme or an FULV scheme according to a model result. According to the method, precision and individuation of chemotherapy are achieved, unnecessary toxic and side effects are reduced, the life quality and lifetime of a patient are improved, and the problems that in the prior art, dependence on experience, single data dimension, no dynamic adjustment mechanism and poor stability are solved. Therefore, the problems of low response rate of oxaliplatin and obvious side effect are solved.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a compound based on the 6-methylfurano[2,3-d]pyrimidine-4(3H)-one structure, its preparation method, and its applications. The compound provided by this invention, based on the 6-methylfurano[2,3-d]pyrimidine-4(3H)-one structure, enhances the chelation effect between the compound and zinc ions in histone deacetylases by combining the pharmacophore of a DNA methyltransferase 3A inhibitor with an isohydroxamic acid fragment, thus exhibiting strong HDAC inhibitory activity while maintaining DNMT3A inhibition. The compound provided by this invention shows significantly higher inhibitory activity against human non-small cell lung cancer cells H460 than against H460 DNMT3A-HDAC6 double knockout cells, demonstrating in vivo activity against human non-small cell lung cancer and possessing application value as a therapeutic agent for diseases and disorders related to DNMT3A and HDAC6.

This invention discloses the application of methylene blue in the preparation of drugs for treating lymphoma, belonging to the field of therapeutic drug technology. This invention creatively discovers that methylene blue can be used as a drug for treating lymphoma, exhibiting cytotoxic effects against human diffuse large B-cell lymphoma cell lines including U2932, TMD8, SUDHL-4, and OCI-LY19, as well as human peripheral T-cell lymphoma cell lines including KARPAS299, SMZ-1, and KHYG-1, and its in vitro activity is superior to first-line chemotherapy drugs. This invention provides an effective option for researching lymphoma treatment strategies and preparing new drugs for treating lymphoma.

This invention in one aspect discloses a smartport system that can continuously monitor cardiovascular function during chemotherapy sessions through ECG and dynamic ejection fraction measurements via ultrasound probes. Ultrasound probes monitor the patency of the catheter shaft through Doppler measurements of the flow. Monitoring heart function and patency of the catheter shaft are unmet needs for chemotherapy patients who receive drugs via portacath systems. This monitoring allows immediate real-time assessment of the cardiotoxicity of cytotoxic chemotherapeutic therapies.

The application discloses an application of a small molecule inhibitor of stress granules in preparation of a tumor treatment drug, and relates to the technical field of biological medicines.The small molecule inhibitor of stress granules, i.e., compound UA-0007373, is obtained by high-throughput screening of "ChemDiv Protein-Protein Interaction (PPI) Library". The small molecule inhibitor can effectively inhibit the formation of cell stress granules caused by G3BP1, thereby reducing the drug resistance of tumor cells. The small molecule inhibitor can effectively inhibit the formation of stress granules induced by an anticancer drug through cell experiments. Therefore, the application provides a new auxiliary compound for the chemical drug treatment of cancer, and can provide a new technical thought for the research and development of cancer drugs.

The invention relates to the technical field of biology, in particular to application of a PHB2 protein or a coding gene of the PHB2 protein in preparation of a medicine for regulating and controlling adipogenesis. The invention discovers that the PHB2 protein, the encoding gene of the PHB2 protein or the biological material containing the encoding gene can regulate and control the adipogenesis for the first time, and the effect of inhibiting the adipogenesis is achieved by improving the activity of the PHB2 protein or improving the expression quantity of the encoding gene. Therefore, the PHB2 protein and the encoding gene of the PHB2 protein can be used as a target for preparing a medicine for regulating and controlling adipogenesis, a medicine for treating animal obesity and a product for regulating and controlling adipocyte differentiation, and can also be used as a target for screening the medicine for regulating and controlling the adipogenesis. The invention provides a new technical scheme for solving the problem of chicken abdominal fat deposition.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.